ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today
LOS ANGELES, May 06, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that leading independent proxy advisory firm Institutional Shareholder Services (“ISS”) has recommended that ACELYRIN stockholders vote “FOR” the proposed merger (“Proposed Transaction”) of the Company with Alumis Inc. (Nasdaq:ALMS).
Read more at globenewswire.comThis article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/AI%20(artificial%20intelligence)/Ai%20chip%20by%20Quality%20Stock%20Arts%20via%20Shutterstock.jpg)
/A%20close-up%20of%20the%20Broadcom%20logo%20on%20a%20smartphone%20by%20Timon%20via%20Adobe%20Stock.jpeg)